JP2022031784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022031784A5 JP2022031784A5 JP2021190474A JP2021190474A JP2022031784A5 JP 2022031784 A5 JP2022031784 A5 JP 2022031784A5 JP 2021190474 A JP2021190474 A JP 2021190474A JP 2021190474 A JP2021190474 A JP 2021190474A JP 2022031784 A5 JP2022031784 A5 JP 2022031784A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- chimeric antigen
- sequence shown
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023098770A JP2023116716A (ja) | 2018-04-12 | 2023-06-15 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
| JP2025051295A JP2025098166A (ja) | 2018-04-12 | 2025-03-26 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810326346.9A CN110372796B (zh) | 2018-04-12 | 2018-04-12 | 靶向bcma的嵌合抗原受体及其制法和应用 |
| CN201810326346.9 | 2018-04-12 | ||
| JP2020531444A JP7148611B2 (ja) | 2018-04-12 | 2019-04-02 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
| PCT/CN2019/081064 WO2019196713A1 (zh) | 2018-04-12 | 2019-04-02 | 靶向bcma的嵌合抗原受体及其制法和应用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531444A Division JP7148611B2 (ja) | 2018-04-12 | 2019-04-02 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023098770A Division JP2023116716A (ja) | 2018-04-12 | 2023-06-15 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022031784A JP2022031784A (ja) | 2022-02-22 |
| JP2022031784A5 true JP2022031784A5 (enExample) | 2022-09-15 |
| JP7299294B2 JP7299294B2 (ja) | 2023-06-27 |
Family
ID=68162957
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531444A Active JP7148611B2 (ja) | 2018-04-12 | 2019-04-02 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
| JP2021190474A Active JP7299294B2 (ja) | 2018-04-12 | 2021-11-24 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
| JP2023098770A Pending JP2023116716A (ja) | 2018-04-12 | 2023-06-15 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
| JP2025051295A Pending JP2025098166A (ja) | 2018-04-12 | 2025-03-26 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531444A Active JP7148611B2 (ja) | 2018-04-12 | 2019-04-02 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023098770A Pending JP2023116716A (ja) | 2018-04-12 | 2023-06-15 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
| JP2025051295A Pending JP2025098166A (ja) | 2018-04-12 | 2025-03-26 | Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11142581B2 (enExample) |
| EP (1) | EP3778651A4 (enExample) |
| JP (4) | JP7148611B2 (enExample) |
| KR (1) | KR102966142B1 (enExample) |
| CN (3) | CN116836297A (enExample) |
| AU (2) | AU2019251016B2 (enExample) |
| CA (1) | CA3095827A1 (enExample) |
| SG (1) | SG11202009962UA (enExample) |
| WO (1) | WO2019196713A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116836297A (zh) * | 2018-04-12 | 2023-10-03 | 上海赛比曼生物科技有限公司 | 靶向bcma的嵌合抗原受体及其制法和应用 |
| CN111333732B (zh) * | 2019-12-17 | 2023-02-28 | 中国药科大学 | 一种靶向人bcma且激活nk细胞的双特异性抗体的制备及其应用 |
| KR102371151B1 (ko) * | 2020-03-13 | 2022-03-07 | 주식회사 큐로셀 | 항-bcma 결합 영역, 이를 포함하는 융합단백질, 및 이를 포함하는 조성물 |
| CN112851815B (zh) * | 2020-03-17 | 2023-08-08 | 西安宇繁生物科技有限责任公司 | 抗bcma抗体或其抗原结合片段及其制备方法和应用 |
| CN113527507A (zh) * | 2020-04-16 | 2021-10-22 | 上海赛比曼生物科技有限公司 | 靶向cd22的嵌合抗原受体及其制法和应用 |
| CN113637073B (zh) | 2020-05-11 | 2024-04-12 | 上海赛比曼生物科技有限公司 | Bcma抗体及其制备和应用 |
| CN112251412B (zh) * | 2020-10-12 | 2023-03-28 | 汤朝阳 | 一种靶向bcma的嵌合抗原受体t细胞及其应用 |
| US20240000839A1 (en) * | 2020-12-02 | 2024-01-04 | Shanghai Cellular Biopharmaceutical Group Ltd. | Bcma-targeted chimeric antigen receptors |
| AU2021393434A1 (en) * | 2020-12-02 | 2023-06-22 | Shanghai AbelZeta Ltd. | Bcma-targeted chimeric antigen receptors |
| JP2024500189A (ja) | 2020-12-21 | 2024-01-04 | アロジーン セラピューティクス，インコーポレイテッド | プロテアーゼ活性化ｃｄ４５ゲートｃａｒ |
| CN113024671B (zh) * | 2020-12-31 | 2022-05-24 | 北京艺妙神州医药科技有限公司 | 一种抗bcma的抗体及其应用 |
| MX2023008809A (es) | 2021-01-29 | 2023-08-04 | Allogene Therapeutics Inc | ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS. |
| US20240059782A1 (en) * | 2022-03-01 | 2024-02-22 | Agilent Technologies, Inc. | Anti-human b cell maturation antigen (bcma) antibodies and their use in immunohistochemistry (ihc) |
| US20240042030A1 (en) | 2022-07-29 | 2024-02-08 | Allogene Therapeutics, Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
| CN116251188A (zh) * | 2023-01-09 | 2023-06-13 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | Stat1抑制剂在制备b细胞淋巴癌放射增敏药物中的应用及该药物 |
| PE20260290A1 (es) | 2023-03-31 | 2026-02-10 | Abelzeta Inc | Receptores de antigeno quimericos biespecificos dirigidos a cd20 y bcma |
| CN116444669B (zh) * | 2023-04-04 | 2024-02-13 | 科弈(浙江)药业科技有限公司 | 靶向bcma car-t细胞人源化抗体 |
| KR20260105764A (ko) | 2023-10-30 | 2026-07-07 | 알로젠 테라퓨틱스 인코포레이티드 | 조작된 세포 |
| CN119119274B (zh) * | 2024-09-26 | 2026-08-11 | 北京昌盛鸿途生物科技有限公司 | 一种靶向bcma的cart细胞及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| EP2714737A1 (en) * | 2011-05-27 | 2014-04-09 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) -binding proteins |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| AU2013246443B2 (en) * | 2012-04-11 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting B-cell maturation antigen |
| EP3131927B8 (en) * | 2014-04-14 | 2020-12-23 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| EP3172231B1 (en) * | 2014-07-24 | 2021-05-05 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| US10383929B2 (en) * | 2014-12-12 | 2019-08-20 | Bluebird Bio, Inc. | BCMA chimeric antigen receptors |
| GB201503742D0 (en) * | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| TWI700298B (zh) * | 2015-04-13 | 2020-08-01 | 美商輝瑞股份有限公司 | 靶向ｂ細胞成熟抗原之嵌合型抗原受體類 |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| EP3368903A1 (en) * | 2015-10-30 | 2018-09-05 | GlaxoSmithKline Intellectual Property Development Limited | Prognostic method |
| US20190112380A1 (en) * | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| WO2017210617A2 (en) | 2016-06-02 | 2017-12-07 | Porter, David, L. | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
| US12048718B2 (en) * | 2016-06-07 | 2024-07-30 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft | Chimeric antigen receptor and CAR-T cells that bind BCMA |
| PL3896091T3 (pl) * | 2016-08-10 | 2024-04-29 | Legend Biotech Ireland Limited | Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania |
| MX2019005277A (es) | 2016-11-04 | 2019-09-27 | Bluebird Bio Inc | Composiciones de celulas t con car anti-bcma. |
| CN107827989A (zh) * | 2017-10-18 | 2018-03-23 | 银丰生物工程集团有限公司 | 靶向骨髓瘤bcma抗原的转基因t细胞及其制备方法与应用 |
| CN116836297A (zh) * | 2018-04-12 | 2023-10-03 | 上海赛比曼生物科技有限公司 | 靶向bcma的嵌合抗原受体及其制法和应用 |
| JP7599205B2 (ja) | 2018-06-01 | 2024-12-13 | アンヘレス セラピューティクス インコーポレイテッド | 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化 |
| MX2021001083A (es) | 2018-07-31 | 2021-03-31 | Amgen Res Munich Gmbh | Regimen posologico para anticuerpos biespecificos contra bcma-cd3. |
-
2018
- 2018-04-12 CN CN202310450645.4A patent/CN116836297A/zh active Pending
- 2018-04-12 CN CN202310447932.XA patent/CN116514995A/zh active Pending
- 2018-04-12 CN CN201810326346.9A patent/CN110372796B/zh active Active
-
2019
- 2019-04-02 SG SG11202009962UA patent/SG11202009962UA/en unknown
- 2019-04-02 AU AU2019251016A patent/AU2019251016B2/en active Active
- 2019-04-02 JP JP2020531444A patent/JP7148611B2/ja active Active
- 2019-04-02 EP EP19784803.9A patent/EP3778651A4/en active Pending
- 2019-04-02 CA CA3095827A patent/CA3095827A1/en active Pending
- 2019-04-02 KR KR1020207032269A patent/KR102966142B1/ko active Active
- 2019-04-02 WO PCT/CN2019/081064 patent/WO2019196713A1/zh not_active Ceased
-
2020
- 2020-05-22 US US16/881,668 patent/US11142581B2/en active Active
-
2021
- 2021-09-16 US US17/476,661 patent/US11498973B2/en active Active
- 2021-11-24 JP JP2021190474A patent/JP7299294B2/ja active Active
-
2022
- 2022-09-23 US US17/951,774 patent/US12637516B2/en active Active
-
2023
- 2023-06-15 JP JP2023098770A patent/JP2023116716A/ja active Pending
- 2023-06-29 AU AU2023204159A patent/AU2023204159B2/en active Active
-
2025
- 2025-03-26 JP JP2025051295A patent/JP2025098166A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7857236B2 (ja) | 免疫活性化Ｆｃドメイン結合分子 | |
| TWI633121B (zh) | 雙特異性活化ｔ細胞之抗原結合分子 | |
| EP3954707A1 (en) | Protease cleavable bispecific antibodies and uses thereof | |
| WO2022057871A1 (zh) | 抗4-1bb-抗pd-l1双特异性抗体、其药物组合物及用途 | |
| CN111171155B (zh) | 抗cd3和cd123双特异性抗体及其用途 | |
| Guo et al. | Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment | |
| CN113272330A (zh) | 一种双特异抗体 | |
| JP2022527081A5 (enExample) | ||
| WO2023246701A1 (zh) | 一种抗体及其用途 | |
| US20230340119A1 (en) | Composition of triax antibodies and method of making and using thereof | |
| WO2023186077A1 (zh) | 抗pd-1单克隆抗体及其衍生物和用途 | |
| JP2026514663A (ja) | Ｔｎｆスーパーファミリーメンバー免疫サイトカイン及びその使用 | |
| EP3983013A1 (en) | Immune checkpoint blocking bispecific molecules | |
| WO2025148933A1 (zh) | 抗体及其药物偶联物和用途 | |
| WO2025162031A1 (zh) | 一种靶向TfR1的单域抗体及其应用 | |
| CN121752591A (zh) | 异源二聚体Fc分子及其用途 | |
| JP2023521218A5 (enExample) | ||
| JP2023513800A5 (enExample) | ||
| JP2024513700A (ja) | 抗ワクシニアウイルス抗原抗体並びに関連する組成物及び方法 | |
| CN116063512B (zh) | 多功能重组抗体及其制备方法和应用 | |
| US20260055188A1 (en) | Bispecific antibody and use thereof | |
| Sun et al. | Discovery of a novel mesothelin specific human antibody VH domain | |
| CN117586408A (zh) | 一种结合tnfr2和b7h3的双特异性抗体 | |
| CN116355099A (zh) | 重组抗人ox40和pd-l1双特异抗体及应用 | |
| TW202615479A (zh) | 細胞激素受體促效劑 |